Noninvasive Prenatal Screening (NIPS)
22q11.2 deletion syndrome and fetal RhD status for RhD negative patients is now available.
Empowering Expecting Parents
Noninvasive prenatal screening (NIPS) can provide expecting mothers the knowledge needed to make medical decisions regarding pregnancy, including the decision to pursue more invasive testing methods. NIPS is the best option for expecting patients to predict the likelihood of certain chromosome aneuploidies such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13), and sex chromosome aneuploidies. Fetal sex can also be reported.
NIPS is endorsed by the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) as an appropriate screening option for all pregnant patients, regardless of maternal age.
Note: NIPS is a screening test; it does not provide a diagnosis.
4-6 Calendar Days
Average turnaround for results
Fetal Sex
Optional fetal sex determination
10 Weeks
Available at 10 weeks gestation
Singleton & Twin
Pregnancies supported*
*22q11.2 deletion screening and fetal RhD status are not available for twin pregnancies.
Conditions Screened For
Trisomies
Sex Chromosome Aneuploidies
Microdeletions
Fetal RhD Screening
Download our patient brochure
About Our Test
Additional Resources
Comparing Noninvasive Prenatal Screening & Maternal Serum Screening
NIPS, which uses cell-free DNA testing, is currently the most sensitive and specific screening test for common fetal aneuploidies involving chromosomes 21, 18, 13, X, and Y with optional fetal sex detection. Traditional maternal serum screening (MSS) typically screens for only trisomy 21 and trisomy 18. In addition to being a more accurate test, NIPS can be performed earlier in pregnancy than most MSS options and requires only a single maternal blood draw. Here's a table that can help you decide which prenatal genetic screening option is the best for your patient.
| Screening Approach | Gestational Age of Collection | Fetal Sex Detected | Trisomy 21 Detection Rate | Number of Collections Required | |
| NIPS | 10 Weeks to Term | Yes | 99% | 1 | |
| Quad Screening | 15-22 Weeks | No | 81% | 1 | |
Integrated
| 10-13 Then 15-22 Weeks | No | 96% | 2 | |
| Sequential Screening | 10-13 Then 15-22 Weeks | No | 95% | 2 |